Target Information
| Target General Information | Top | |||||
|---|---|---|---|---|---|---|
| Target ID |
T54093
(Former ID: TTDI02029)
|
|||||
| Target Name |
T-box transcription factor T (TBXT)
|
|||||
| Synonyms |
T; Protein T
Click to Show/Hide
|
|||||
| Gene Name |
T
|
|||||
| Target Type |
Clinical trial target
|
[1] | ||||
| Disease | [+] 2 Target-related Diseases | + | ||||
| 1 | Pituitary gland disorder [ICD-11: 5A60-5A61] | |||||
| 2 | Solid tumour/cancer [ICD-11: 2A00-2F9Z] | |||||
| Function |
Involved in the transcriptional regulation of genes required for mesoderm formation and differentiation. Binds to a palindromic site (called T site) and activates gene transcription when bound to such a site.
Click to Show/Hide
|
|||||
| UniProt ID | ||||||
| Sequence |
MSSPGTESAGKSLQYRVDHLLSAVENELQAGSEKGDPTERELRVGLEESELWLRFKELTN
EMIVTKNGRRMFPVLKVNVSGLDPNAMYSFLLDFVAADNHRWKYVNGEWVPGGKPEPQAP SCVYIHPDSPNFGAHWMKAPVSFSKVKLTNKLNGGGQIMLNSLHKYEPRIHIVRVGGPQR MITSHCFPETQFIAVTAYQNEEITALKIKYNPFAKAFLDAKERSDHKEMMEEPGDSQQPG YSQWGWLLPGTSTLCPPANPHPQFGGALSLPSTHSCDRYPTLRSHRSSPYPSPYAHRNNS PTYSDNSPACLSMLQSHDNWSSLGMPAHPSMLPVSHNASPPTSSSQYPSLWSVSNGAVTP GSQAAAVSNGLGAQFFRGSPAHYTPLTHPVSAPSSSGSPLYEGAAAATDIVDSQYDAAAQ GRLIASWTPVSPPSM Click to Show/Hide
|
|||||
| 3D Structure | Click to Show 3D Structure of This Target | AlphaFold | ||||
| Drugs and Modes of Action | Top | |||||
|---|---|---|---|---|---|---|
| Clinical Trial Drug(s) | [+] 1 Clinical Trial Drugs | + | ||||
| 1 | GI-6301 | Drug Info | Phase 2 | Chordoma | [2], [3] | |
| Cell-based Target Expression Variations | Top | |||||
|---|---|---|---|---|---|---|
| Cell-based Target Expression Variations | ||||||
| Drug Binding Sites of Target | Top | |||||
|---|---|---|---|---|---|---|
| Ligand Name: N-{4-[(3-Chloro-4-Fluorophenyl)amino]-7-[(3s)-Tetrahydrofuran-3-Yloxy]quinazolin-6-Yl}-4-(Dimethylamino)butanamide | Ligand Info | |||||
| Structure Description | Crystal structure of human Brachyury G177D variant in complex with Afatinib | PDB:6ZU8 | ||||
| Method | X-ray diffraction | Resolution | 1.95 Å | Mutation | No | [4] |
| PDB Sequence |
ELRVGLEESE
50 LWLRFKELTN60 EMIVTKNGRR70 MFPVLKVNVS80 GLDPNAMYSF90 LLDFVAADNH 100 RWKYVNGEWV110 PGGKPEPQAP120 SCVYIHPDSP130 NFGAHWMKAP140 VSFSKVKLTN 150 KLNGGGQIML160 NSLHKYEPRI170 HIVRVRMITS184 HCFPETQFIA194 VTAYQNEEIT 204 ALKIKYNPFA214 KAFLHHHHH
|
|||||
|
|
||||||
| Ligand Name: N-[4-(2-amino-1,3-thiazol-4-yl)phenyl]acetamide | Ligand Info | |||||
| Structure Description | PanDDA analysis group deposition -- Crystal Structure of human Brachyury G177D variant in complex with Z48847594 | PDB:5QS9 | ||||
| Method | X-ray diffraction | Resolution | 1.43 Å | Mutation | Yes | [5] |
| PDB Sequence |
ELRVGLEESE
50 LWLRFKELTN60 EMIVTKNGRR70 MFPVLKVNVS80 GLDPNAMYSF90 LLDFVAADNH 100 RWKYVNGEWV110 PGGKPEPQAP120 SCVYIHPDSP130 NFGAHWMKAP140 VSFSKVKLTN 150 KLNGGGQIML160 NSLHKYEPRI170 HIVRVGDPQR180 MITSHCFPET190 QFIAVTAYQN 200 EEITALKIKY210 N
|
|||||
|
|
||||||
| Click to View More Binding Site Information of This Target with Different Ligands | ||||||
| Different Human System Profiles of Target | Top |
|---|---|
|
Human Similarity Proteins
of target is determined by comparing the sequence similarity of all human proteins with the target based on BLAST. The similarity proteins for a target are defined as the proteins with E-value < 0.005 and outside the protein families of the target.
A target that has fewer human similarity proteins outside its family is commonly regarded to possess a greater capacity to avoid undesired interactions and thus increase the possibility of finding successful drugs
(Brief Bioinform, 21: 649-662, 2020).
Human Similarity Proteins
|
|
|
There is no similarity protein (E value < 0.005) for this target
|
| Target Affiliated Biological Pathways | Top | |||||
|---|---|---|---|---|---|---|
| Panther Pathway | [+] 1 Panther Pathways | + | ||||
| 1 | Wnt signaling pathway | |||||
| PID Pathway | [+] 2 PID Pathways | + | ||||
| 1 | Regulation of nuclear beta catenin signaling and target gene transcription | |||||
| 2 | Validated transcriptional targets of deltaNp63 isoforms | |||||
| References | Top | |||||
|---|---|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of GlobeImmune. | |||||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
| REF 4 | Crystal structure of human Brachyury G177D variant in complex with Afatinib | |||||
| REF 5 | PanDDA analysis group deposition | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.